MREO: Pomerantz Law Firm’s Class Action Alert!

Company Overview and Recent Developments

Mereo BioPharma Group plc (NASDAQ: MREO) is a U.K.-based clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases and oncology (www.mereobiopharma.com). Its lead candidate, setrusumab (also known as UX143), was being co-developed with Ultragenyx for osteogenesis imperfecta (OI, a rare bone disorder). In late 2025, Mereo announced that two Phase 3 trials of setrusumab – the Orbit and Cosmic studies – failed to meet their primary endpoints of reducing fracture rates, although both showed statistically significant improvements in bone mineral density (www.globenewswire.com). This news sent Mereo’s stock price plunging ~88% in a single day (from around $2.30 to $0.28 on December 29, 2025) (www.globenewswire.com). The dramatic collapse in market value has triggered shareholder lawsuits: Pomerantz LLP has filed a class-action lawsuit alleging that Mereo and certain officers may have misled investors or engaged in securities fraud surrounding the trial disclosures (www.prnewswire.com). (Investors who purchased MREO during the class period have until April 6, 2026 to seek lead-plaintiff status in the case (www.prnewswire.com).) This backdrop sets a challenging scene for Mereo, as management grapples with the fallout of the trial failure and legal actions while formulating next steps for the company’s pipeline.

Dividend Policy and Shareholder Returns

Mereo has never paid any dividends to shareholders, and it does not anticipate doing so in the foreseeable future (cdn.yahoofinance.com). As a development-stage biotech, the company has prioritized conserving capital for R&D over returning cash to investors. Management explicitly states that all available funds and future earnings are intended to fund expansion of the business and product development rather than dividends (cdn.yahoofinance.com). Consequently, MREO’s dividend yield is 0%, and shareholders’ returns hinge entirely on capital appreciation (or depreciation) of the stock. Traditional cash flow metrics like Funds From Operations (FFO/AFFO) are not applicable to Mereo’s current operations, since the company has no recurring revenues or profits – indeed, it has never generated product revenue to date (cdn.yahoofinance.com). Instead, the company’s “shareholder returns” have come mainly through changes in stock price (which recently have been sharply negative following the trial results). Notably, Mereo’s share count has increased over time as the company issues equity to fund its activities, meaning existing shareholders have been diluted in exchange for the capital needed to advance its drug candidates (cdn.yahoofinance.com).

Capital Structure, Liquidity, and Leverage

Mereo’s capital structure is financed predominantly by equity. The company has raised roughly $209 million in capital since 2020 via private and public offerings (including an at-the-market sale in July 2023) (cdn.yahoofinance.com). This steady reliance on equity financing has kept balance-sheet debt low. As of early 2026, Mereo carries minimal debt – it previously had a £3.8 million (≈$5 million) convertible loan note from Novartis that matured in February 2025 (cdn.yahoofinance.com), which was either converted or repaid by that maturity. No significant new borrowings have been reported since, leaving the company largely debt-free aside from routine liabilities. This conservative leverage position means no looming debt maturities or interest burdens that could strain the company in the near term.

Liquidity remains adequate in the wake of the setrusumab setback. Mereo held approximately $41 million in cash and equivalents as of December 31, 2025, an amount management now expects can fund operations until mid-2027 (www.stocktitan.net). This extended runway is partly due to cost-cutting measures: after the Phase 3 failure, Mereo delayed certain pre-commercial and manufacturing activities for setrusumab to preserve cash while the program’s future is reassessed (www.panabee.com) (www.panabee.com). With an annual operating burn rate in the teens of millions of dollars, $41 million should cover at least 18+ months of baseline expenses. The company’s interest coverage is a non-issue given the lack of substantial debt (interest expense was negligible in 2025) (www.mereobiopharma.com). In summary, Mereo’s balance sheet liquidity appears sufficient for the near term, but longer-term funding needs will depend on whether it initiates new clinical trials (such as a Phase 3 for its other drug alvelestat) or secures partnership funding. Equity dilution remains the fallback financing mechanism if additional cash is required, as Mereo has no recurring cash flows or borrowing capacity to rely on (cdn.yahoofinance.com) (cdn.yahoofinance.com).

Valuation and Trading Metrics

After the late-2025 collapse in share price, MREO stock is now trading at levels that imply a valuation scarcely above the company’s cash on hand. At ~$0.30 per ADS (post-crash), Mereo’s market capitalization is roughly on the order of $45 million, nearly equivalent to its ~$41 million cash reserve (www.globenewswire.com) (www.stocktitan.net). In effect, the enterprise value (market cap minus net cash) is approaching zero – indicating that the market assigns virtually no value to Mereo’s drug pipeline or other assets at present. This depressed valuation reflects investors’ skepticism after the failure of setrusumab; the pipeline’s future prospects are highly uncertain, so the stock is behaving like a “cash box” biotech. For context, Mereo’s tangible book value at September 30, 2025 was about $46.6 million (www.mereobiopharma.com), so the stock is trading near book value (P/B ≈1x). Traditional earnings-based multiples are not meaningful since Mereo has no earnings (the company continues to post net losses each quarter). Another metric sometimes applied to biotechs is enterprise value to cash burn. Given a ~$4 million enterprise value and an annual cash burn in the $20–25 million range, MREO’s EV/burn ratio is <0.2× – an unusually low figure that underscores the market’s pessimism. Essentially, investors are valuing only the cash and giving almost no credit to the pipeline, implying expectations of further value destruction. This could represent an option value opportunity (if any pipeline asset succeeds against the odds, the upside could be significant from this base) but also suggests a high risk of dilution or asset writedowns if prospects don’t improve. It is worth noting that Mereo’s American Depositary Shares (ADS) structure (5 ordinary shares per ADS) means the company has a large share count – about 159 million ADS equivalent outstanding as of Q3 2025 (www.mereobiopharma.com) – which can make achieving a higher per-share price challenging without a reverse split or major positive catalyst.

Risks and Red Flags

Mereo BioPharma faces a number of significant risks and red flags following recent events:

– Lead Asset Failure: The biggest risk is the failure of setrusumab to meet primary endpoints. This was Mereo’s lead asset, and its setback raises serious doubts about the company’s ability to ever bring a product to market. There is no guarantee regulators will accept bone density improvements as a basis for approval in OI when fracture reduction wasn’t demonstrated (www.globenewswire.com) (www.panabee.com). Without a viable path forward for setrusumab, Mereo’s future revenue prospects are severely diminished.

– Pipeline Concentration & R&D Risk: Mereo’s remaining pipeline is limited and unproven. The next key asset, alvelestat (for alpha-1 antitrypsin deficiency lung disease), is still pre-Phase 3 – it will require a large trial (~220 patients over 18 months) and success is uncertain (www.panabee.com). The company will likely need a development/commercial partner for alvelestat, as it cannot easily fund a Phase 3 alone. If no partnership materializes, that program could stall. Other pipeline elements (e.g. the oncology antibody navicixizumab and rare bone disease drug vantictumab) have been out-licensed to partners, so their progress (and any milestone payments to Mereo) is largely outside the company’s control (www.panabee.com). Essentially, Mereo has no approved products and no guaranteed revenue, and its R&D programs could fail or face delays as many biotech projects do (cdn.yahoofinance.com).

– Financial and Dilution Risk: While Mereo has cash to last into 2027 at the current burn rate (www.stocktitan.net), this assumes a very minimal pipeline spend. Any decision to initiate a major trial (for example, if it proceeds with alvelestat on its own) or unexpected costs could shorten the runway. With the stock price at mere pennies, any new equity raise would be massively dilutive at these levels. The company might be forced to execute a reverse stock split to regain Nasdaq compliance if the ADS continues to trade below $1 (to avoid delisting). A low market cap and low share price also make the stock illiquid and constrain the ability to tap capital markets for funding (cdn.yahoofinance.com). There is a real risk that, absent improvement in its prospects, Mereo’s cash will dwindle to a point where it becomes a going-concern risk or a takeover target at a bargain price.

– Legal and Reputational Risk: The recently filed securities class action lawsuit is an overhang for the company (www.prnewswire.com). The lawsuit alleges that Mereo’s management may have made false or misleading statements regarding setrusumab’s trials, which, if proven, could result in financial penalties or settlements (often paid by insurance, but still a distraction) and reputational damage. Even if the case is ultimately dismissed or settled without admission of guilt (as is common), it will consume management time and legal expenses. The allegations highlight that investors felt blindsided by the trial outcome – a red flag in terms of management’s communication and credibility with shareholders.

– Governance and Strategic Direction: There have been past governance issues and shareholder disputes. In 2022, Mereo’s largest shareholder, Rubric Capital, launched a proxy fight demanding board seats and strategic changes (www.mereobiopharma.com) – signaling dissatisfaction with how the company was being run. Although that contest was settled (with some board refreshment) before the Phase 3 results, the fact it occurred is a red flag. Now, with the strategy upended by the OI trial failure, there is a risk that activist shareholders could resurface, pushing for more drastic measures (such as restructuring, asset sales, or even liquidation to return remaining cash to investors). Internal management turnover is also a risk; if key scientists or executives depart after the setback, it could further destabilize the company’s efforts.

– Market Conditions: Broader market conditions for biotech are challenging, especially for small-cap, pre-revenue companies. Investor appetite for funding high-risk drug development is currently limited, so Mereo might struggle to raise additional capital or secure partnerships on favorable terms. In the rare disease space, larger competitors or better-funded peers could also outmaneuver Mereo. For instance, any competing therapy in development for OI or AATD could make it harder for Mereo’s programs to justify investment. With no steady revenue, Mereo is entirely at the mercy of clinical trial outcomes and capital market conditions – a precarious position.

Overall, the risks surrounding MREO are high, and the recent events have accentuated concerns about shareholder dilution, clinical failure, and leadership’s decision-making. These red flags warrant careful consideration for any current or prospective investor.

Open Questions and Unknowns

Looking ahead, several open questions will determine Mereo’s fate and are on investors’ minds:

– Can setrusumab be salvaged in any way? Although the Phase 3 trials missed their primary fracture-reduction goals, they did show strong bone density gains. In a disease with no approved treatments, will regulators consider those BMD improvements as a basis for some limited approval or surrogate endpoint? Or will additional trials be required (which may be untenable)? How Ultragenyx and Mereo proceed with setrusumab – whether by seeking regulatory feedback on the existing data or abandoning the program – remains unclear (www.panabee.com).

– Will Mereo secure a partner for alvelestat? Management has signaled a pivot to alvelestat (for AATD lung disease) as the next focus, and importantly has aligned with FDA and EMA on a Phase 3 trial design (www.panabee.com). However, funding this trial is a big question – Mereo is actively seeking a partnership to support and commercialize alvelestat (www.panabee.com). If a partnership (or other non-dilutive financing) doesn’t materialize, can Mereo afford to initiate the trial on its own, or will the program be delayed indefinitely? The timing of any deal, and the terms (e.g. will Mereo have to give up substantial rights in exchange for funding?), will greatly influence the company’s prospects.

– How will the class action lawsuit play out? The Pomerantz-led lawsuit alleges that Mereo misled investors about the setrusumab trials (www.prnewswire.com). While such suits are common after biotech stock crashes, the outcome is uncertain. Will an internal investigation or discovery in the case reveal any material missteps by management in trial disclosures? The case could take months or years to resolve. A dismissal or modest settlement would remove the legal overhang, but an adverse finding could further harm Mereo’s finances or reputation. Investors will be watching for any updates on this legal front, though it may largely be handled by insurers and lawyers in the background.

– Will there be strategic changes or activism? In the wake of the setrusumab failure, Mereo’s board and shareholders must reassess the company’s strategy. One open question is whether the company will consider strategic alternatives – for example, selling off assets, merging with another biotech, or even winding down. The prior activism by Rubric Capital in 2022 demonstrated that there is willingness among shareholders to push for change if the status quo is untenable (www.mereobiopharma.com). With the stock at a fraction of its former value, there is a possibility of renewed activist campaigns or outside interest (e.g. could a larger pharma swoop in to acquire Mereo mainly for its cash and any remaining pipeline value?). How proactively the board navigates these pressures – whether they make preemptive changes or wait for activist agitation – is an unknown.

– Can partnered programs create upside? Mereo does have a couple of partnered programs in its portfolio. Vantictumab, a Wnt-pathway antibody for a rare bone disease (ADO2), is now under development by partner Ǟshibio, with a Phase 2 trial expected to start in 2026 (www.panabee.com). Similarly, the oncology antibody navicixizumab is out-licensed to Feng (OncXerna) and could generate milestone payments if development progresses (cdn.yahoofinance.com) (cdn.yahoofinance.com). An open question is whether any of these partnered assets will hit key milestones that result in cash inflows or new value for Mereo. Positive news from partners (for instance, Ǟshibio advancing vantictumab) could provide a much-needed boost in confidence and potentially validate parts of Mereo’s R&D platform. However, these are longer-term possibilities – nothing immediate is guaranteed.

Ultimately, Mereo’s future hangs on its ability to adapt after the major setback. Will the company manage to extract any value from the remnants of its OI program or refocus successfully on a new lead program, or will it become another biotech cautionary tale? The next few quarters – as partnership talks progress and as regulators give feedback on setrusumab’s data – should provide some answers. For now, investors in MREO are essentially betting on management’s next moves and the slim hope that what remains of the pipeline can still translate into shareholder value in the long run. (www.panabee.com) (www.panabee.com)

For informational purposes only; not investment advice.